Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market

Journals

REMEDIUM

The periodical about the pharmaceutical and medical equipment markets

ROSSIYSKIE APTEKI

(Russian pharmacies) - specialized periodical edition for pgarmacy professionals

MEDITSINSKY SOVET

Medical Council - Scientific Journal for Physicians


Home / News

13.10.2015

40mg Copaxone approved in Russia

Teva Global Specialty Medicines CEO: 70% of US patients currently receiving Copaxone take the 40 mg/mL formulation.

Teva Pharmaceutical Industries Ltd.  announced that the Russian Ministry of Health has approved the Marketing Authorization license (MA) for three-times-a-week Copaxone (glatiramer acetate injection) 40 mg/mL. This formulation of the multiple sclerosis treatment will allow for a less frequent dosing regimen for patients with the illnessin Russia.

Teva president and CEO of Global Specialty Medicines Rob Koremans said, “The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for the multiple sclerosis patient community in Russia. The new three-times-a-week Copaxone 40 mg/mL is the same therapy that patients and physicians know and trust with almost 60% fewer injections per year compared to the current daily Copaxone 20 mg/mL formulation. In the US., for example, more than 70% of patients currently receiving glatiramer acetate treatment are receiving the Copaxone 40 mg/mL formulation.”

Daily Copaxone 20 mg, approved in Russia in 2010, continues to be available in Russia.


Source:  http://www.globes.co.il

Remedium group

REMEDIUM

publishing house

CLIFAR

programmer of electronic software products

R-PRESS

advertisement agency

REPRENT

rent-a-rep company